Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$11.48M
Enterprise ValueAU$5.17
Total Cash (Recent Filing)AU$8.09M
Total Debt (Recent Filing)AU$180.92K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding637,981,000
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
Bulls Say, Bears Say
Bulls Say
Platform Network And Multi‑side ModelMedAdvisor operates a multi-sided digital platform connecting pharmacies, patients and pharmaceutical brands, creating durable engagement and potential network effects. This model supports recurring service revenue and long-term partnerships that can be monetized through adherence programs and brand services.
Improving Free Cash FlowReported free cash flow growth of 18.49% signals improving cash generation versus prior periods. Sustained FCF improvement can extend runway, fund product development or restructuring without immediate equity raises, and provide financial optionality to support strategic execution over the medium term.
Operational Efficiency Signal (ROE Positive)A positive return on equity indicates management can extract returns from invested capital, implying operational levers can generate value even under stress. If sustained, this efficiency supports recovery prospects and better capital allocation as revenue stabilizes or grows.
Bears Say
Sharp Revenue ContractionA deep revenue decline of ~39% undermines scale economics and reduces the base for fixed-cost absorption. Prolonged top-line shrinkage pressures margins, weakens bargaining power with partners, and makes it harder to sustain investment in product and sales necessary for medium-term recovery.
Severely Negative ProfitabilityExtremely negative margins and negative EBIT/EBITDA indicate structural profitability issues and high operating leverage. Without material cost restructuring or revenue recovery, persistent losses will erode liquidity and limit ability to invest in growth or maintain platform capabilities over the coming months.
Stressed Balance Sheet And Negative EquityNegative shareholders' equity and an extreme debt-to-equity ratio signal solvency and financing risks. This structural weakness constrains access to capital, increases likelihood of dilution or restructuring, and reduces strategic flexibility to invest in product or market expansion.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.01 and its highest was AU$0.08 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$11.48M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 23 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,981,000 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Oneview Healthcare Chess Depository Interests repr 1
―
PharmX Technologies
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―